Andreas Erdmann
Papers
1
Total Citations
32
H-Index
1
About
Andreas Erdmann is a leading clinical researcher in urothelial carcinoma, with a primary focus on perioperative chemoimmunotherapy for muscle-invasive bladder cancer. His major contribution is pioneering the integration of immune checkpoint inhibitors with standard cisplatin-based chemotherapy before surgery. Specifically, he led the SAKK 06/17 phase II trial, which demonstrated that combining durvalumab with cisplatin/gemcitabine is safe and shows promising efficacy in operable muscle-invasive urothelial carcinoma. This work, presented at ASCO 2020, has garnered 32 citations and represents a critical step toward improving outcomes for patients who face high relapse rates after standard neoadjuvant chemotherapy alone. Erdmann’s research directly addresses the urgent need for more effective, bladder-sparing or survival-extending strategies. His contributions are shaping the evolving landscape of perioperative immunotherapy, positioning him as a key figure in the transition from chemotherapy-only to chemoimmunotherapy regimens for high-risk bladder cancer.
Research Focus
Key Achievements
Top Papers
- 1